Cannabix Technologies (BLO) AI Stock Analysis

• Market Cap: C$65.38M
• Dividend Yield: N/A
• Average Volume (3M): 36.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: N/A
• EPS Growth: -52.41%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 121,074,104
• 10 Day Avg. Volume: 30,616
• 30 Day Avg. Volume: 36,452
• PEG Ratio: -0.30
• Price to Book (P/B): 27.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -37.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$0.49 ▼(-18.33% Downside)
• Action: Reiterated Date: 01/04/26
• Date: Action: Reiterated 01/04/26

The score is primarily held down by very weak financial performance (minimal revenue, large losses, and ongoing cash burn) despite low leverage. Technical indicators are modestly supportive in the near term, but valuation is constrained by negative earnings and no dividend data.

Positive Factors

Low leverage / balance sheet

Very low reported debt reduces near-term solvency risk and interest burden, providing the company financial optionality while it invests in product development. This durable strength means the firm can focus on R&D or raise capital without high fixed financing costs for several months.

Focused niche product portfolio

The company has a clear, focused product strategy around breath-based cannabis and alcohol detection with stated end-markets (workplace, law enforcement, personal testing). Specialization with prototypes and R&D creates a durable product roadmap and clearer commercialization pathways if technical validation continues.

Evidence of cash-flow improvement

Although cash flow remains negative overall, documented improvement in free cash flow in some periods signals that operational efficiency or revenue progress can materially reduce burn. If sustained, this trend supports a multi-month path toward lower financing needs and steadier operations.

Negative Factors

Minimal revenue, deep losses

Reported trailing revenues are negligible versus operating scale, and gross profit is below zero. This indicates the business is not yet commercially scaled; persistent negative margins mean the firm must materially grow sales or reduce costs to ever reach sustainable profitability over the coming months.

Sustained cash burn

A recurring ~-$2.0M operating and free cash flow profile creates ongoing funding pressure. Over a 2-6 month horizon this persistent burn necessitates external financing or rapid commercial traction; otherwise the company risks curtailing R&D or facing dilutive capital raises.

Eroding equity and negative returns

Material declines in shareholders' equity and strongly negative ROE reflect cumulative losses and possible dilution. This erodes investor capital and makes future equity raises more dilutive, weakening long-term capacity to fund growth without adverse shareholder impact.

Cannabix Technologies Business Overview & Revenue Model

Company Description

Cannabix Technologies Inc., a technology company, develops marijuana breathalyzer for employers, law enforcement, governments, and public in North America. It develops tetrahydrocannabinol breath analyzers, a point of care breath testing tool for the rapid detection of recent cannabis use, as well as breath collection units. The company was formerly known as West Point Resources Inc. and changed its name to Cannabix Technologies Inc. in August 2014. Cannabix Technologies Inc. was incorporated in 2011 and is based in Burnaby, Canada.

How the Company Makes Money

Cannabix Technologies makes money primarily through the development and sale of its breathalyzer devices designed to detect cannabis usage. Revenue is generated from the sales of these devices to law enforcement agencies, employers, and other entities interested in cannabis detection technology. The company may also have potential revenue streams from licensing its technology to other firms and entering into strategic partnerships for distribution and development. However, specific data on these activities is not available.

Cannabix Technologies Financial Statement Overview

Summary

Income statement and cash flow are very weak: minimal TTM revenue (~$0.12M), deeply negative profitability, and continued cash burn (TTM operating and free cash flow about -$2.0M). The balance sheet is a partial offset with low leverage (~$0.09M debt; ~0.05x debt-to-equity), but equity has declined and returns are strongly negative, keeping overall financial quality low.

Income Statement

TTM (Trailing-Twelve-Months) revenue is minimal (~$0.12M) and profitability is deeply negative, with gross profit below zero and large operating and net losses (net margin roughly -51x sales). Annual results also show limited/zero revenue in recent years alongside persistent losses, suggesting the company has not yet reached commercial scale and is still in a heavy investment/burn phase. The main positive is that losses appear tied to operating structure rather than leverage, but the current earnings profile is very weak.

Balance Sheet

Leverage is low, with modest total debt (~$0.09M TTM) and a low debt-to-equity ratio (~0.05x), which reduces near-term balance-sheet risk. However, equity has declined materially versus prior years, and returns on equity are strongly negative, reflecting ongoing losses and dilution/erosion of shareholder value. Overall, the balance sheet looks lightly levered but pressured by continued unprofitability.

Cash Flow

Cash generation remains negative: TTM operating cash flow is about -$2.0M and free cash flow is about -$2.0M, indicating continued cash burn to fund operations. While free cash flow has shown improvement in some periods (including a strong TTM growth figure off a negative base), cash flows are still firmly negative and not yet supported by meaningful operating inflows. Free cash flow tracks net losses closely, implying limited non-cash cushioning and continued funding needs.

Breakdown	TTM	Jul 2025	Jul 2024	Jul 2023	Jul 2022	Jul 2021
Income Statement
Total Revenue	123.04K	0.00	0.00	0.00	0.00	6.57M
Gross Profit	-83.38K	-168.52K	-153.24K	-126.29K	-29.22K	-25.57K
EBITDA	-6.14M	-4.55M	-2.96M	-2.01M	-3.11M	-9.11M
Net Income	-6.33M	-4.69M	-3.13M	-2.14M	-3.37M	-9.24M
Balance Sheet
Total Assets	2.17M	3.00M	4.70M	6.95M	8.76M	10.38M
Cash, Cash Equivalents and Short-Term Investments	1.60M	2.35M	4.26M	6.52M	8.45M	10.10M
Total Debt	88.43K	158.65K	154.58K	132.54K	0.00	0.00
Total Liabilities	304.70K	447.71K	248.02K	237.17K	120.84K	80.78K
Stockholders Equity	1.87M	2.55M	4.45M	6.71M	8.64M	10.30M
Cash Flow
Free Cash Flow	-2.05M	-1.86M	-2.11M	-2.00M	-2.13M	-1.79M
Operating Cash Flow	-2.04M	-1.84M	-2.08M	-1.97M	-2.13M	-1.71M
Investing Cash Flow	0.00	-17.54K	-30.96K	-28.65K	-4.59K	-121.81K
Financing Cash Flow	277.08K	-58.47K	-143.53K	10.88K	492.50K	3.49M

Cannabix Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLO, the sentiment is Negative. The current price of 0.6 is above the 20-day moving average (MA) of 0.56, above the 50-day MA of 0.58, and above the 200-day MA of 0.57, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.17 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BLO.

Cannabix Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QIPT	55 Neutral	C$221.44M	-36.01	-10.51%	―	2.48%	-53.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VPT	50 Neutral	C$20.61M	-5.28	―	―	28.59%	23.46%
BLO	46 Neutral	C$65.38M	-17.95	-188.03%	―	―	-52.41%
PINK	42 Neutral	C$66.84M	-1.50	-181.70%	―	209.29%	35.38%

Cannabix Technologies Corporate Events

Cannabix Technologies Raises C$700,000 in Non-Brokered Private Placement

Cannabix Technologies has closed a non-brokered private placement, raising C$700,000 through the issuance of 1.4 million units priced at C$0.50, each comprising one common share and a warrant exercisable at C$0.65 for 24 months with an acceleration feature tied to share price performance. The proceeds will be directed toward manufacturing inventory and labour, general and administrative costs, investor relations, and working capital, with the financing conducted under the listed issuer financing exemption, involving CEO participation deemed a related-party transaction and modest finder’s fees and warrants, while an existing investor waived its contractual participation right for this offering.

The placement units are freely tradable under Canadian securities rules due to the chosen exemption, potentially enhancing liquidity for new investors and supporting Cannabix’s near-term operational funding needs. Insider participation, though below the threshold requiring minority approval, signals internal confidence in the company’s trajectory, while the investor waiver helped streamline the financing and underscores the company’s ability to access capital without diluting pre-existing participation rights in this round.

The most recent analyst rating on (TSE:BLO) stock is a Hold with a C$0.62 price target. To see the full list of analyst forecasts on Cannabix Technologies stock, see the TSE:BLO Stock Forecast page.

Cannabix Marijuana Breath Test Lands Cover Spot in AlcoPro’s 2026 Catalogue

Cannabix Technologies’ Marijuana Breath Test (MBT) has been selected to appear on the cover of AlcoPro Inc.’s 2026 product catalogue, which is distributed to more than 85,000 businesses in the U.S. and abroad, including law enforcement and corrections clients. The feature underscores Cannabix’s growing partnership with AlcoPro in pre-launch marketing of the MBT in the U.S. and highlights the company’s integration of proprietary breath collection technology with LC-MS analysis through its collaboration with Omega Laboratories, positioning Cannabix to gain greater visibility and credibility in the professional drug-testing market as employers seek more accurate and non-invasive tools to address evolving workplace safety and impairment challenges.

The most recent analyst rating on (TSE:BLO) stock is a Hold with a C$0.62 price target. To see the full list of analyst forecasts on Cannabix Technologies stock, see the TSE:BLO Stock Forecast page.

Cannabix Wins First International BreathLogix Order, Scraps Planned Financing

Cannabix Technologies has secured its first international distributor order for its BreathLogix autonomous alcohol screening devices and accessories from its exclusive Australian partner, Breathalyser Sales & Service Pty Ltd, covering Australia, New Zealand and the Pacific Islands. The BreathLogix system offers rapid pre-access breath alcohol checks, identity-confirming photos, real-time alerts and cloud-based reporting, and can be integrated with site access controls and fleet management systems, positioning it for deployment across industries such as mining, oil and gas, industrial and logistics. Featuring a patent-pending pre-calibrated sensor cartridge to simplify maintenance, the product launch momentum has prompted Cannabix to cancel a planned non-brokered private placement and reassess its near-term capital needs in early 2026, while the company also initiates a short investor awareness campaign to broaden market visibility.

The most recent analyst rating on (TSE:BLO) stock is a Hold with a C$0.59 price target. To see the full list of analyst forecasts on Cannabix Technologies stock, see the TSE:BLO Stock Forecast page.

Cannabix Technologies’ Marijuana Breath Test Achieves Key Regulatory Milestone

Cannabix Technologies Inc. announced a significant milestone for its Marijuana Breath Test (MBT) system as its Breath Collection Unit (BCU) passed the Federal Communications Commission’s electronic emissions testing. This achievement is crucial for the system’s commercialization in the U.S. and Canadian markets, where the company is completing necessary regulatory steps. The MBT system, which includes proprietary Breath Cartridges, is designed to collect and preserve breath samples for analysis, and Cannabix is working with Omega Laboratories to advance its commercialization. The successful emissions testing positions Cannabix favorably in the market, potentially impacting stakeholders by advancing the availability of reliable marijuana testing technology.